www.fdanews.com/articles/67541-innexus-and-epitomics-enter-into-a-co-development-agreement-for-therapeutic-transmab-antibodies
INNEXUS AND EPITOMICS ENTER INTO A CO-DEVELOPMENT AGREEMENT FOR THERAPEUTIC TRANSMAB ANTIBODIES
January 13, 2005
InNexus Biotechnology has entered into a co-development arrangement for its TransMab Antibody Technology with Epitomics of Burlingame, Calif. Under the terms of the agreement; Epitomics will supply humanized antibodies for certain intracellular targets that have been identified by the parties. InNexus will then modify these antibodies for intracellular delivery using its TransMab Technology. The companies plan to then jointly move the lead therapeutic candidate(s) through clinical trials Phase II, before licensing to a commercialization partner.